[go: up one dir, main page]

HK1202877A1 - Anti-cd98 antibodies and methods of use thereof - Google Patents

Anti-cd98 antibodies and methods of use thereof Download PDF

Info

Publication number
HK1202877A1
HK1202877A1 HK15103289.7A HK15103289A HK1202877A1 HK 1202877 A1 HK1202877 A1 HK 1202877A1 HK 15103289 A HK15103289 A HK 15103289A HK 1202877 A1 HK1202877 A1 HK 1202877A1
Authority
HK
Hong Kong
Prior art keywords
antibodies
methods
cancers
bind
diagnosis
Prior art date
Application number
HK15103289.7A
Other languages
Chinese (zh)
Inventor
John Lippincott
Edward Thein Htun Van Der Horst
Joseph Zachwieja
Hoang Tran
Original Assignee
伊格尼卡生物治疗公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 伊格尼卡生物治疗公司 filed Critical 伊格尼卡生物治疗公司
Publication of HK1202877A1 publication Critical patent/HK1202877A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention provides antibodies that bind CD98, and methods of use of the antibodies in the diagnosis and treatment of cancers.
HK15103289.7A 2011-11-23 2012-11-21 Anti-cd98 antibodies and methods of use thereof HK1202877A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161563443P 2011-11-23 2011-11-23
US61/563,443 2011-11-23
PCT/US2012/066347 WO2013078377A1 (en) 2011-11-23 2012-11-21 Anti-cd98 antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
HK1202877A1 true HK1202877A1 (en) 2015-10-09

Family

ID=47295209

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15103289.7A HK1202877A1 (en) 2011-11-23 2012-11-21 Anti-cd98 antibodies and methods of use thereof

Country Status (15)

Country Link
EP (1) EP2782935A1 (en)
JP (1) JP2015501639A (en)
KR (1) KR20140125351A (en)
CN (1) CN104302669A (en)
AU (1) AU2012340623A1 (en)
BR (1) BR112014012590A8 (en)
CA (1) CA2856873A1 (en)
HK (1) HK1202877A1 (en)
IL (1) IL232755A0 (en)
MX (1) MX2014006272A (en)
PH (1) PH12014501164A1 (en)
RU (1) RU2014124530A (en)
SG (1) SG11201402619VA (en)
WO (1) WO2013078377A1 (en)
ZA (1) ZA201403760B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3027071A1 (en) 2011-01-14 2013-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
US20140363454A1 (en) * 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Antibody-Drug Conjugates, Compositions and Methods of Use
WO2014197866A1 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Modified antibodies and related compounds, compositions, and methods of use
JP2017114763A (en) * 2014-03-26 2017-06-29 第一三共株式会社 Anti-CD98 antibody-drug conjugate
CA2966365A1 (en) * 2014-12-10 2016-06-16 Genentech, Inc. Blood brain barrier receptor antibodies and methods of use
CA2995166C (en) * 2015-08-10 2023-10-31 Osaka University Anti-cd98 antibody
CN105385694B (en) * 2015-11-20 2019-01-18 中国人民解放军第四军医大学 Anti-human CD98 monoclonal antibody 98-3H3 light and heavy chain variable region gene and its application
WO2017214462A2 (en) * 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
EP3468598A1 (en) * 2016-06-08 2019-04-17 AbbVie Inc. Anti-cd98 antibodies and antibody drug conjugates
JP2019522643A (en) * 2016-06-08 2019-08-15 アッヴィ・インコーポレイテッド Anti-CD98 antibodies and antibody drug conjugates
IL300274A (en) 2016-06-08 2023-04-01 Abbvie Inc Anti-b7-h3 antibodies and antibody drug conjugates
JP7779653B2 (en) 2018-02-07 2025-12-03 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Methods and compositions for therapeutic protein delivery
EP3715370A1 (en) 2019-03-28 2020-09-30 Technische Universität München High affinity anticalins directed against human cd98hc
CA3179922A1 (en) * 2020-04-08 2021-10-14 Janssen Biotech, Inc. Anti-cd98 antibodies and uses thereof
AR124681A1 (en) 2021-01-20 2023-04-26 Abbvie Inc ANTI-EGFR ANTIBODY-DRUG CONJUGATES
US20250084177A1 (en) * 2021-06-02 2025-03-13 Huahui Health Ltd. Anti-cd98 antibodies and uses thereof
AU2022401024A1 (en) 2021-11-30 2024-05-16 Daiichi Sankyo Company, Limited Protease-cleavable masked antibodies
WO2023109956A1 (en) * 2021-12-17 2023-06-22 Biocytogen Jiangsu Co., Ltd. Genetically modified non-human animal with human or chimeric cd98hc
KR20240141757A (en) 2022-02-09 2024-09-27 다이이찌 산쿄 가부시키가이샤 Environmentally responsive masking antibodies and their uses
CN118027195B (en) * 2023-05-06 2025-07-04 合肥天港免疫药物有限公司 Affinity-matured MICA antibodies and their applications
KR20250017151A (en) * 2023-07-21 2025-02-04 세종대학교산학협력단 Anti cd98 monoclonal antibody and its use thereof
WO2025055904A1 (en) * 2023-09-12 2025-03-20 4B Technologies (Beijing) Co., Limited Cd98hc antibody and use thereof
WO2025152912A1 (en) * 2024-01-15 2025-07-24 4B Technologies (Suzhou) Limited Cd98hc antigen-binding protein and use thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
JPH02500329A (en) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド Targeted multifunctional protein
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572A7 (en) 1991-10-07 1994-05-27 Oncologix Inc Combination and method of use of anti-erbB-2 monoclonal antibodies
NL9101953A (en) 1991-11-21 1993-06-16 Seed Capital Investments TESTING DEVICE CONTAINING A PLATE WITH A MULTIPLE OF WELLS WITH AN ASSOCIATED DOSING DEVICE, AND A KIT INCLUDING THESE DEVICES AND USE OF THE DEVICES.
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
DE69334255D1 (en) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker for cancer and biosynthetic binding protein for it
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
DK0672142T3 (en) 1992-12-04 2001-06-18 Medical Res Council Multivalent and multi-specific binding proteins as well as their preparation and use
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT1068241E (en) 1998-04-02 2007-11-19 Genentech Inc Antibody variants and fragments thereof
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR101077001B1 (en) 1999-01-15 2011-10-26 제넨테크, 인크. Polypeptide Variants with Altered Effector Function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
EP1197755A1 (en) 2000-10-11 2002-04-17 Pepscan Systems B.V. Identification of protein binding sites
ES2327905T3 (en) 2001-10-01 2009-11-05 Dyax Corp. MULTI-CHAIN EUCARIOT PRESENTATION VECTORS AND USES OF THE SAME.
WO2003035842A2 (en) 2001-10-24 2003-05-01 Dyax Corporation Hybridization control of sequence variation
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
CN101065151B (en) 2004-09-23 2014-12-10 健泰科生物技术公司 Cysteine engineered antibodies and conjugates
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
SI1934174T1 (en) 2005-10-07 2011-08-31 Exelixis Inc Azetidines as mek inhibitors for the treatment of proliferative diseases
TWI390034B (en) * 2006-04-06 2013-03-21 Kyowa Hakko Kirin Co Ltd Novel anti-CD98 antibody
GB0615662D0 (en) * 2006-08-07 2006-09-13 Affitech As Antibody
EP2554552B1 (en) * 2010-03-26 2015-05-13 The University of Tokushima Novel anti-cd98 antibody and use thereof

Also Published As

Publication number Publication date
KR20140125351A (en) 2014-10-28
CN104302669A (en) 2015-01-21
EP2782935A1 (en) 2014-10-01
CA2856873A1 (en) 2013-05-30
NZ626513A (en) 2017-02-24
WO2013078377A1 (en) 2013-05-30
ZA201403760B (en) 2017-09-27
SG11201402619VA (en) 2014-10-30
AU2012340623A1 (en) 2014-07-17
BR112014012590A2 (en) 2017-06-20
BR112014012590A8 (en) 2017-12-19
MX2014006272A (en) 2014-10-24
JP2015501639A (en) 2015-01-19
IL232755A0 (en) 2014-07-31
RU2014124530A (en) 2015-12-27
PH12014501164A1 (en) 2014-10-20
WO2013078377A9 (en) 2013-08-08

Similar Documents

Publication Publication Date Title
HK1202877A1 (en) Anti-cd98 antibodies and methods of use thereof
HK1200468A1 (en) Anti-erbb3 antibodies and uses thereof
IL235261B (en) Antibodies against claudin 18.2 useful in cancer diagnosis
WO2013177055A3 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
MX2014008102A (en) Dual variable domain immunoglobulins against receptors.
HK1200321A1 (en) Bispecific immunobinders directed against tnf and il-17
WO2012121775A3 (en) Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
WO2014144280A8 (en) DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
EP3043819A4 (en) Anti-vstm5 antibodies and the use thereof in therapy and diagnosis
PH12013500207A1 (en) Dual variable domain immunoglobulins and uses thereof
PH12013500337A1 (en) Dual variable domain immunoglobulins and uses thereof
PH12013500867A1 (en) Dual variable domain immunoglobulins and uses thereof
WO2012177595A9 (en) Compositions and methods for the therapy and diagnosis of cancer
WO2014176475A3 (en) Egfr inhibitors and uses thereof
WO2012166626A8 (en) Reagents and methods for treating dental disease
WO2015009740A3 (en) Anti-mucin 1 binding agents and uses thereof
WO2015017146A3 (en) Antibodies with ultralong complementarity determining regions
WO2014106001A3 (en) Dual specific binding proteins having a receptor sequence
WO2015058132A3 (en) Anti-rsp02 and/or anti-rsp03 antibodies and their uses
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
WO2013106747A3 (en) Methods and compositions for the treatment and diagnosis of thyroid cancer
MX2015010023A (en) Anti-cd83 antibodies and use thereof.
EP3150632A3 (en) Anti-ricin antibodies and uses thereof
WO2015013233A3 (en) Methods and compositions for the treatment and diagnosis of bladder cancer
HK1203379A1 (en) β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF